drugset / Trial / NCT01193062
Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274
RandomizedParallel-groupDouble-blindOther
Summary
The primary purpose of the study is to evaluate the effect of PF-04995274 on cerebrospinal fluid levels of soluble Amyloid precursor protein fragments and Amyloid beta fragments following single oral dose in healthy volunteers. Safety and tolerability of PF-04995274 single dose administration in healthy volunteers will also be assessed as part of the objectives.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04995274 | Small molecule | 0.1 mg | Oral |
| Subject | PF-04995274 | Small molecule | 10 mg | Oral |
| Subject | PF-04995274 | Small molecule | 15 mg | Oral |
| Subject | PF-04995274 | Small molecule | 40 mg | Oral |
Indications
No indication recorded.